Antiviral composition comprising epidermal growth factor receptor inhibitors as an effective component

摘要

The present invention relates to the development of an antiviral composition comprising an epidermal growth factor receptor inhibitor as an active ingredient. Extracellular SARS-CoV-2 RNA that measures how much virus is reduced in infected cells by infecting SARS-CoV-2 after treatment with HEK293T cells using a drug library previously used as an epidermal growth factor receptor inhibitor Efficacy was evaluated by analyzing copy number and nucleocapsid protein. Through this, 9 types of epithelial growth receptor inhibitors that are effective in the treatment of SARS-CoV-2 were discovered.